BODI stock forecast, quote, news & analysis
The Beachbody Co Inc is a fitness and nutrition company providing fitness, nutrition, and stress-reducing programs to its customers... Show more
Why The Beachbody Company (BODI) Is Up +37% in the Last 30 Days
Key Takeaways
- BODI stock surged +37% over the past 30 days, driven by positive analyst sentiment and product launches amid a volatile but upward trend.
- Over the past quarter, the stock rose +26%, reflecting sustained profitability from recent earnings beats and strategic business shifts.
- Key drivers include Q4 2025 earnings with net income and positive EBITDA, analyst upgrades signaling up to 33% upside, and new P90X supplements boosting market sentiment.
- Transition from multi-level marketing to omni-channel model improved margins despite revenue declines, supporting stock resilience.
- Strong relative performance versus consumer discretionary peers highlights improving fundamentals and growth outlook.
The Beachbody Company (BODI) Company Overview and Market Position
The Beachbody Company, Inc. (BODI) is a leading fitness and nutrition company offering digital subscription platforms like BODi for workouts, nutrition plans, and connected fitness equipment. Its core business model has shifted from a multi-level marketing (MLM) structure to an omni-channel approach, emphasizing direct-to-consumer digital subscriptions, retail nutrition products, and affiliate marketing. Operating in the competitive health and wellness industry, BODI competes with platforms like Peloton and WW International (PTON), but differentiates through iconic brands like P90X and cost-efficient operations. This transformation has bolstered fundamentals with higher gross margins (74.5% in Q4 2025) and positive cash flow, directly explaining recent stock price strength as investors reward profitability gains.
The Beachbody Company (BODI) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, BODI stock climbed +37% from a closing price of approximately $8.68 to $11.90, exhibiting volatile but trend-driven movement with surges around earnings and news events, interspersed with pullbacks. In the past quarter, shares advanced +26% from around $9.42, showing steady recovery amid broader market choppiness, with a 50-day range of $6.96 to $12.31 underscoring range-bound volatility before recent highs. The stock outperformed the S&P 500 and consumer discretionary sector, reflecting company-specific catalysts over macroeconomic pressures.
What Drove BODI Stock Price in the Last 30 Days
BODI's 30-day rally stemmed primarily from heightened analyst optimism and product innovation. Wall Street reports highlighted up to 33.52% upside potential, with consensus price targets implying 29.83% gains, fueled by earnings momentum. The launch of P90X Performance Supplements with advanced "P90X-Factor" ingredients targeted workouts and recovery, enhancing brand visibility and retail expansion sentiment. A 6.1% single-day surge reflected broader confidence in FY2026 growth. Sector outperformance versus consumer discretionary peers amplified buying, as BODI's relative price strength drew investors amid choppy markets. These factors connected directly to price spikes, like post-earnings jumps from $8.33 to $10.91 around March 11.
What Drove BODI Stock Performance Over the Last Quarter
The quarter's +26% gain built on sustained profitability narratives from Q4 and FY2025 results, marking the first full year of positive operating income since 2021. Despite 35.7% revenue drop to $55.5 million from exiting MLM and connected fitness, net income hit $5.2 million (second straight quarter) and adjusted EBITDA rose 48% to $12.9 million, beating guidance. Gross margins expanded 400 basis points to 74.5% via cost discipline and omni-channel shifts. Institutional interest grew with Zacks Rank #2 (Buy) and outperformance versus peers down 7.4% YTD. Macro wellness trends and lower breakeven thresholds (via expense cuts) provided tailwinds, with cumulative earnings beats (e.g., Q3 EPS $0.51 vs. -$0.54 expected) driving the upward trajectory.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots from hundreds available, which analyze and trade thousands of tickers across various markets. These bots employ diverse strategies—such as trend-following, mean reversion, or momentum—over short-term, swing, or long-term timeframes, with performance metrics like win rate, profit factor, and Sharpe ratio clearly displayed. Curated for relevance and recent success, the section helps traders identify bots suited to current market trends, like volatility in consumer stocks. Explore Trending AI Robots to integrate data-driven automation into your trading toolkit.
BODI Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor Q1 2026 earnings for progress on nutrition retail rollout and subscriber growth in BODi digital (0.87 million in Q4). Upcoming product expansions, like lower-priced nutrition SKUs and P90X updates, could signal FY2026 revenue inflection. Industry trends in at-home fitness demand, competition from PTON, and macro factors like consumer spending amid interest rates remain key. Risks include seasonal revenue fluctuations (stronger Q1-Q2) and execution on omni-channel transition; catalysts like further analyst upgrades or positive free cash flow guidance could sway sentiment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Momentum Indicator for BODI turns negative, indicating new downward trend
BODI saw its Momentum Indicator move below the 0 level on June 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 96 similar instances where the indicator turned negative. In of the 96 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for BODI turned negative on June 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 10-day moving average for BODI crossed bearishly below the 50-day moving average on May 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BODI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for BODI entered a downward trend on June 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BODI's RSI Oscillator exited the oversold zone, of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BODI advanced for three days, in of 229 cases, the price rose further within the following month. The odds of a continued upward trend are .
BODI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.880) is normal, around the industry mean (9.494). P/E Ratio (12.219) is within average values for comparable stocks, (31.555). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (31.912). BODI has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (0.273) is also within normal values, averaging (57.758).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BODI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BODI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement